HOLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hologic Inc (HOLX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show a slight bullish trend, the financial performance and analyst sentiment are not compelling enough to justify an immediate investment. The lack of significant positive catalysts and the recent downgrade by analysts suggest a cautious approach.
The technical indicators show a slight bullish trend. The MACD is positive and expanding, the RSI is neutral at 69.819, and the moving averages (SMA_5 > SMA_20 > SMA_200) indicate bullish momentum. However, the stock is trading near key resistance levels (R1: 75.657, R2: 75.834), which could limit immediate upside potential.
Hedge funds are significantly increasing their positions in HOLX, with a 4616.24% increase in buying activity over the last quarter. Gross margin improved by 1.53% YoY in the latest quarter.
Financial performance shows a decline in net income (-10.90% YoY) and EPS (-9.20% YoY).
In Q1 2026, revenue increased by 2.54% YoY to $1.048 billion. However, net income dropped by 10.90% YoY to $179.1 million, and EPS fell by 9.20% YoY to $0.79. Gross margin improved slightly to 57.21%, up 1.53% YoY.
Evercore ISI downgraded Hologic to In Line from Outperform, with a reduced price target of $78 (down from $79). This reflects a cautious sentiment from analysts.
